H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,

Slides:

Advertisements

Similar presentations

Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I Eriksson.

Advertisements

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

Oral Apixaban For The Treatment of Acute Venous Thromboembolism

Results: 1.Progression of thrombus length and volume (40% vs. 28%; P

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Venous thromboembolism: how long to treat?

Anticoagulation and Thrombosis Management

Oral anticoagulant therapy : a look to the future Alexander G. G. Turpie Department of Medicine HHS-General Hospital Hamilton, Canada.

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Unprovoked DVT in a young patient

Are all Xa Inhibitors the Same. Alexander G. G

The Definitive Thrombosis Update

Oral rivaroxaban alone for the treatment of symptomatic pulmonary embolism: the EINSTEIN PE study Harry R Büller on behalf of the EINSTEIN Investigators.

The EINSTEIN PE Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Pulmonary Embolism.

Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.

The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.

EINSTEIN DVT and EINSTEIN PE Pooled Analysis

Anticoagulation and Thrombosis Management

Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

ARIXTRA® (fondaparinux sodium) in the prevention of venous thromboembolism after hip-fracture surgery BI Eriksson, KA Bauer, MR Lassen, and AGG Turpie.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

Dodson Thompson, DO Northlakes Community Clinic Minong, WI.

Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

Thrombosis Management in Cardiology: The relevance of direct Factor Xa inhibition Prevention and Treatment of Venous Thromboembolism Alexander G G Turpie.

Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Oral Rivaroxaban for Symptomatic Venous Thromboembolism.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Polly Rimtepathip Pharm D. Candidate September 16, 2011 Outpatient Versus Inpatient Treatment for Patients with Acute Pulmonary Embolism: an International,

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after major knee surgery KA Bauer, BI Eriksson,

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism 1 (RECORD 1 ) Journal Club General Surgery Rotation.

Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.

Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing June 2012 NICE clinical guideline.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.

Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism David Jime´nez1, Drahomir Aujesky2, Gema.

Date of download: 6/22/2016 From: An Evaluation of d-Dimer in the Diagnosis of Pulmonary Embolism: A Randomized Trial Ann Intern Med. 2006;144(11):

Outpatient DVT assessment & treatment Daniel Gilada.

How I treat recurrent deep-vein thrombosis by Paul A. Kyrle Blood Volume 127(6): February 11, 2016 ©2016 by American Society of Hematology.

The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism A.Sam, D. Sa´nchez, V. Go´mez, C. Wagner,

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

VTE Guidelines: 2016 update

Postoperative Calf Venous Thrombosis: Location, Location, Location

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.

Ortho Warfarin Dosing Protocol

(p < for group 1 or 2 vs. group 3)

Oral Anticoagulation and Preventing Stent Thrombosis

Extended Treatment of VTE: Who is the Right Candidate?

Long-Term Treatment of VTE: Case Studies

The Safety and Efficacy of Full vs

Timing the First Postoperative Dose of Anticoagulants

New Oral Anticoagulants and VTE Management

Timing the First Postoperative Dose of Anticoagulants

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Anticoagulation and Thrombosis Management

Long-Term Treatment of VTE: Case Studies

Managing Pulmonary Embolism Posthospital Discharge

CONFIDENTIAL--DO NOT REPRODUCE OR DISTRIBUTE

Dipak Patade. NOACs Options for anticoagulation expanding steadily over the past few decades a greater number of agents for prevention and management.

Presentation transcript:

H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva, Switzerland. Treatment of Proximal Deep Vein Thrombosis (DVT): Rivaroxaban Once or Twice Daily Had Similar Efficacy and Safety to Standard Therapy in Phase II Studies

Background: Rivaroxaban is an oral, direct Factor Xa inhibitor Objective: To determine the safety and efficacy of –Once or twice daily dosing of Rivaroxaban –In patients with acute, systomatic, proximal DVT without pulmonary embolism (PE) –Relative to standard therapy heparin/LMWH+vitamin K antagonist [INR 2–3] Treatment of Proximal DVT Buller, H.R. and G. Agnelli. Presented at ISTH 2007 in Geneva, Switzerland, abstract #O-W-052.

Methods: EINSTEIN-DVT (n=543) Patients received: –Rivaroxaban 20 mg once daily (od) –Rivaroxaban 30 mg od –Rivaroxaban 40 mg od –Or standard therapy Efficacy outcome: –Symptomatic, recurrent DVT or symptomatic PE recurrent venous thromboembolism [VTE] –And asymptomatic deterioration on ultrasonography (US) or perfusion lung scan, at 3 months Treatment of Proximal DVT Buller, H.R. and G. Agnelli. Presented at ISTH 2007 in Geneva, Switzerland, abstract #O-W-052.

Methods: ODIXa-DVT (n=613) Patients received: –Rivaroxaban 10 mg twice daily (bid) –Rivaroxaban 20 mg bid –Rivaroxaban 30 mg bid –Or standard therapy Efficacy outcome: –Thrombus regression on ultrasonography without recurrent VTE at 3 weeks –Recurrent VTE and asymptomatic deterioration on ultrasonography at 3 months Treatment of Proximal DVT Buller, H.R. and G. Agnelli. Presented at ISTH 2007 in Geneva, Switzerland, abstract #O-W-052.

Eligible patients: those with symptomatic, proximal DVT at baseline Enoxaparin (1 mg/kg) *Number of patients randomized; CCUS: complete compression ultrasound; PLS: perfusion lung scan; CUS: compression ultrasound Study Designs Buller, H.R. and G. Agnelli. Presented at ISTH 2007 in Geneva, Switzerland, abstract #O-W-052.

Results 20 mg30 mg40 mg60 mg Standard Therapy ODIXa-DVT (bid study) Efficacy outcome (%) /3.0*1.0 Major bleeding (%) /1.7*3.00 EINSTEIN-DVT (od study) Efficacy outcome (%) Major bleeding (%) *Results are shown as 20 mg bid/40 mg bid. Table: Rivaroxaban (total daily dose) Efficacy Outcome at 3 Months 20mg bid40mg bid60mg bid40mg od Standard Therapy Thrombus regression 53.0%59.2%43.8%45.9% Thrombus Regression at 3 Weeks Buller, H.R. and G. Agnelli. Presented at ISTH 2007 in Geneva, Switzerland, abstract #O-W-052.

Conclusion: Rivaroxaban given either once or twice daily had similar efficacy and safety to standard therapy –In patients with acute, systematic, proximal DVT without pulmonary embolism (PE) This oral direct factor Xa inhibitor can be given as the sole treatment in a fixed dose appears to be a very attractive alternative to standard therapy in patients with DVT Treatment of Proximal DVT Buller, H.R. and G. Agnelli. Presented at ISTH 2007 in Geneva, Switzerland, abstract #O-W-052.